Cem Kuscu is an Assistant Professor at The University of Tennessee Health Science Center, specializing in single cell genomics related to liver and kidney diseases and the application of CRISPR technologies in transplantation since September 2018. Prior to this role, Cem Kuscu served as a Research Associate at the University of Virginia from January 2013 to September 2018, focusing on CRISPR-Cas9 gene editing techniques, epigenetics, and combinatorial drug treatments for pancreatic cancer. Earlier experience includes a position as a Research Specialist at Stony Brook University from January 2012 to February 2013, where Cem Kuscu conducted cancer biology research, particularly involving the identification of KIAA1199, which was subsequently renamed "CEMIP," in breast cancer. Cem Kuscu holds a PhD in Cell/Cellular and Molecular Biology from Stony Brook University, a Master of Science from Bilkent University, and a Bachelor's degree in Molecular Biology and Genetics from Middle East Technical University.
